See more : Falken Industries Ltd. (FLKI) Income Statement Analysis – Financial Results
Complete financial analysis of Repligen Corporation (RGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Repligen Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Xiangtan Electrochemical Scientific Co.,Ltd (002125.SZ) Income Statement Analysis – Financial Results
- Pretium Resources Inc. (0VDK.L) Income Statement Analysis – Financial Results
- Kalyani Steels Limited (KSL.NS) Income Statement Analysis – Financial Results
- Africa Oil Corp. (AOI.ST) Income Statement Analysis – Financial Results
- New Oriental Education & Technology Group Inc. (EDU) Income Statement Analysis – Financial Results
Repligen Corporation (RGEN)
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 632.36M | 801.54M | 670.53M | 366.26M | 270.25M | 194.03M | 141.24M | 104.54M | 83.54M | 63.55M | 68.17M | 62.27M | 27.29M | 20.97M | 29.36M | 19.30M | 14.07M | 12.91M | 9.36M | 6.91M | 7.77M | 4.30M | 2.35M | 3.45M | 2.60M | 2.40M | 3.80M | 10.90M | 16.90M | 26.80M | 27.30M | 11.70M | 7.60M | 12.70M | 8.50M | 10.20M | 3.70M | 3.60M |
| Cost of Revenue | 323.54M | 345.83M | 279.28M | 156.63M | 119.10M | 85.95M | 67.05M | 47.12M | 35.25M | 28.02M | 25.16M | 27.17M | 7.12M | 5.51M | 6.78M | 6.16M | 3.61M | 3.55M | 3.89M | 3.25M | 3.48M | 1.99M | 1.12M | 782.23K | 400.00K | 300.00K | 300.00K | 100.00K | -1.10M | 1.50M | -500.00K | -200.00K | -600.00K | 10.50M | 7.60M | 7.20M | 4.40M | 2.60M |
| Gross Profit | 308.83M | 455.71M | 391.25M | 209.63M | 151.15M | 108.08M | 74.19M | 57.42M | 48.29M | 35.53M | 43.01M | 35.10M | 20.17M | 15.46M | 22.58M | 13.14M | 10.46M | 9.36M | 5.47M | 3.67M | 4.29M | 2.31M | 1.22M | 2.67M | 2.20M | 2.10M | 3.50M | 10.80M | 18.00M | 25.30M | 27.80M | 11.90M | 8.20M | 2.20M | 900.00K | 3.00M | -700.00K | 1.00M |
| Gross Profit Ratio | 48.84% | 56.85% | 58.35% | 57.23% | 55.93% | 55.70% | 52.53% | 54.93% | 57.80% | 55.90% | 63.09% | 56.36% | 73.92% | 73.74% | 76.92% | 68.08% | 74.32% | 72.50% | 58.47% | 53.02% | 55.22% | 53.67% | 52.15% | 77.33% | 84.62% | 87.50% | 92.11% | 99.08% | 106.51% | 94.40% | 101.83% | 101.71% | 107.89% | 17.32% | 10.59% | 29.41% | -18.92% | 27.78% |
| Research & Development | 42.72M | 43.94M | 34.27M | 20.18M | 19.45M | 15.77M | 8.67M | 7.36M | 5.74M | 5.61M | 7.34M | 10.49M | 12.53M | 14.16M | 12.77M | 7.24M | 5.92M | 5.16M | 5.04M | 6.48M | 5.23M | 5.36M | 5.79M | 3.75M | 1.80M | 1.40M | 1.40M | 12.30M | 31.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 65.69M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 0.00 | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 631.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 216.89M | 215.83M | 183.87M | 119.62M | 95.61M | 66.32M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 13.23M | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 4.71M | 4.16M | 2.53M | 2.49M | 2.48M | 1.60M | 1.30M | 2.40M | 4.90M | 4.70M | 42.10M | 37.40M | 23.60M | 15.60M | 3.90M | 3.70M | 3.60M | 3.60M | 3.00M |
| Other Expenses | 0.00 | -9.53M | -1.17M | -214.00K | -314.00K | 262.00K | -687.00K | -860.00K | -445.00K | 188.00K | -110.65K | 26.40K | 1.54B | 1.35M | 1.09M | -40.17M | 0.00 | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| Operating Expenses | 261.12M | 259.77M | 218.14M | 139.80M | 115.06M | 82.09M | 60.18M | 38.21M | 30.44M | 22.76M | 20.04M | 23.72M | 20.55M | 21.23M | 18.70M | -22.76M | 12.28M | 10.58M | 9.63M | 13.61M | 9.39M | 7.89M | 8.56M | 6.56M | 3.70M | 2.90M | 4.00M | 18.60M | 38.30M | 44.50M | 39.10M | 24.70M | 16.50M | 4.70M | 4.30M | 4.10M | 4.20M | 3.50M |
| Cost & Expenses | 584.66M | 605.60M | 497.42M | 296.44M | 234.16M | 168.04M | 127.23M | 85.33M | 65.69M | 50.79M | 45.21M | 50.89M | 27.67M | 26.74M | 25.48M | -16.60M | 15.90M | 14.13M | 13.52M | 16.86M | 12.87M | 9.88M | 9.68M | 7.34M | 4.10M | 3.20M | 4.30M | 18.70M | 37.20M | 46.00M | 38.60M | 24.50M | 15.90M | 15.20M | 11.90M | 11.30M | 8.60M | 6.10M |
| Interest Income | 0.00 | 6.98M | 176.00K | 1.74M | 5.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.03M | 1.16M | 12.71M | 12.13M | 9.29M | 6.71M | 6.44M | 3.77M | 32.00K | 49.96K | 49.85K | 56.71K | 26.17K | 1.97K | 2.96K | 2.96K | 0.00 | 696.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 68.56M | 50.99M | 38.45M | 27.07M | 20.87M | 15.78M | 10.45M | 5.33M | 4.59M | 4.02M | 3.11M | 3.51M | 1.67M | 1.38M | 1.08M | 824.63K | 539.03K | 398.43K | 756.26K | 886.71K | 802.23K | 257.54K | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| EBITDA | 127.77M | 246.93M | 211.56M | 101.62M | 58.43M | 41.77M | 24.14M | 24.55M | 22.44M | 15.16M | 26.13M | 14.84M | -30.47K | 1.66M | -3.52M | 6.85M | 36.72M | -1.83M | -1.22M | -2.23M | -8.66M | -4.29M | -5.32M | -7.06M | -4.04M | -2.46M | -615.02K | -2.80M | -6.40M | -17.70M | -16.80M | -9.60M | -11.70M | -7.40M | -1.70M | -2.80M | -600.00K | -4.30M |
| EBITDA Ratio | 20.20% | 23.03% | 25.64% | 19.01% | 13.24% | 13.53% | 9.43% | 17.56% | 20.83% | 20.38% | 33.52% | 18.32% | 4.77% | -20.92% | 16.88% | -28.53% | -15.87% | -15.42% | -48.96% | -101.69% | -62.40% | -149.65% | -388.18% | -105.49% | -7.69% | -25.00% | -10.53% | -25.69% | -37.87% | -62.69% | -35.16% | -100.00% | -132.89% | -14.17% | -32.94% | -21.57% | 310.81% | -86.11% |
| Operating Income | 47.70M | 133.61M | 133.50M | 42.54M | 14.90M | 25.99M | 14.01M | 15.97M | 13.76M | 10.69M | 22.87M | 11.08M | -374.07K | -5.77M | 3.88M | 35.89M | -1.83M | -1.22M | -4.16M | -9.94M | -5.09M | -5.58M | -7.33M | -3.89M | -1.50M | -800.00K | -500.00K | -7.80M | -20.30M | -19.20M | -11.30M | -12.80M | -8.30M | -2.50M | -3.40M | -1.10M | -4.90M | -2.50M |
| Operating Income Ratio | 7.54% | 16.67% | 19.91% | 11.62% | 5.51% | 13.39% | 9.92% | 15.28% | 16.48% | 16.82% | 33.55% | 17.80% | -1.37% | -27.50% | 13.21% | 186.00% | -12.97% | -9.45% | -44.46% | -143.77% | -65.55% | -129.67% | -312.46% | -112.74% | -57.69% | -33.33% | -13.16% | -71.56% | -120.12% | -71.64% | -41.39% | -109.40% | -109.21% | -19.69% | -40.00% | -10.78% | -132.43% | -69.44% |
| Total Other Income/Expenses | 9.00M | -5.53M | -13.71M | -10.61M | -9.93M | -4.55M | -6.76M | -4.28M | -341.00K | 447.58K | 140.82K | -108.34K | -2.35M | 5.72M | 868.07K | 1.89M | 39.76M | 936.07K | 1.92M | 1.18B | 5.40M | 1.12M | 2.05M | 3.52M | 1.86M | 1.96M | 315.02K | 500.00K | 7.80M | 800.00K | 7.90M | 0.00 | 7.10M | 5.90M | 2.50M | 3.70M | 1.10M | 3.50M |
| Income Before Tax | 56.71M | 219.14M | 153.54M | 59.22M | 26.15M | 21.44M | 7.25M | 11.69M | 13.42M | 11.14M | 23.01M | 11.27M | -43.51K | -4.90M | 5.77M | 37.93M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Income Before Tax Ratio | 8.97% | 27.34% | 22.90% | 16.17% | 9.68% | 11.05% | 5.13% | 11.18% | 16.07% | 17.53% | 33.76% | 18.10% | -0.16% | -23.36% | 19.66% | 196.59% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| Income Tax Expense | 21.11M | 33.18M | 25.25M | -709.00K | 4.74M | 4.82M | -21.11M | 11.00K | 4.08M | 2.97M | 6.92M | -2.88M | -330.56K | -834.77K | 26.70K | 827.47K | 889.26K | -696.86K | 2.98M | 9.55M | 4.54M | 4.46M | 5.28M | 3.82M | 2.50M | 800.00K | 500.00K | 11.50M | 32.00M | 19.50M | 11.30M | 12.80M | 5.70M | 2.40M | 3.30M | -300.00K | 20.70M | 1.40M |
| Net Income | 35.60M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M | 9.35M | 8.17M | 16.09M | 14.16M | -43.51K | -4.06M | 5.75M | 37.11M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Net Income Ratio | 5.63% | 23.20% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% | 11.19% | 12.86% | 23.61% | 22.73% | -0.16% | -19.38% | 19.57% | 192.30% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| EPS | 0.64 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 | 0.28 | 0.25 | 0.51 | 0.46 | 0.00 | -0.13 | 0.19 | 1.20 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.75 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| EPS Diluted | 0.63 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 | 0.28 | 0.25 | 0.50 | 0.45 | 0.00 | -0.13 | 0.18 | 1.18 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.74 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| Weighted Avg Shares Out | 55.72M | 55.46M | 55.02M | 52.55M | 48.34M | 43.77M | 38.23M | 33.57M | 32.88M | 32.50M | 31.67M | 30.91M | 30.78M | 30.75M | 30.96M | 30.83M | 30.38M | 30.13M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.37M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
| Weighted Avg Shares Out (Dil) | 56.38M | 57.46M | 57.26M | 53.89M | 49.21M | 45.47M | 39.15M | 34.10M | 33.58M | 33.26M | 32.41M | 31.25M | 30.78M | 30.75M | 31.29M | 31.32M | 30.38M | 30.69M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.53M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates
Repligen (RGEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.92 per share a year ago.
Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first fiscal quarter ended March 31, 2023. Provided in this press release are financial...
Why Repligen Stock Is Sinking Today
Repligen is set to release its first-quarter earnings next Tuesday. Demand for its COVID-related products is declining, and investors appear to be bracing for the company to miss Wall Street's consensus estimates.
Repligen to Report First Quarter 2023 Financial Results
Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET
Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 21-22. ...
Repligen: Exclusive Partnerships And Innovation Set To Drive Growth
Repligen's exclusive partnerships with companies such as DRS Daylight Solutions and Purolite give it a competitive edge in the industry. The company's diverse product line includes pre-packed columns, alternating tangential flow, tangential flow filtration, growth factors, protein A resins, and...
Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates
Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.
Repligen Corporation (RGEN) Q4 2022 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:37 AM ET Repligen Corporation (NASDAQ:RGEN ) Q4 2022 Earnings Conference Call February 22, 2023, 08:30 AM ET Company Participants Tony Hunt - President and CEO Jon Snodgres - CFO Sondra Newman - Head,...
Source: https://incomestatements.info
Category: Stock Reports